BioRestorative Therapies Reports Revenue Growth but Significant Net Loss in Latest 10-Q Filing

BioRestorative Therapies, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending June 30, 2025. The company generated revenues of $303,300 for the three months ended June 30, 2025, a substantial increase from $89,100 in the same period last year. For the six months ending June 30, 2025, total revenues reached $328,300, compared to $124,100 in the prior year. Despite this revenue growth, the company reported a net loss of $2,656,263 for the quarter, an improvement from a net loss of $4,028,562 in the same quarter of 2024. For the six-month period, the net loss was $7,996,062, compared to $6,251,817 in the previous year.

The financial performance reflects a notable increase in operating expenses, which totaled $3,599,858 for the three months ended June 30, 2025, compared to $2,551,417 in the same period of 2024. This increase was primarily driven by higher research and development costs, which rose to $2,225,882 from $1,454,000 year-over-year, as the company continues to invest in its clinical trials and product development initiatives. General and administrative expenses also increased, totaling $1,373,976 for the quarter, up from $1,097,417 in the prior year.

In terms of operational developments, BioRestorative Therapies is advancing its Disc/Spine Program, with its lead product candidate, BRTX-100, undergoing a Phase 2 clinical trial for chronic lower back pain. The company has also entered into a five-year exclusive supply agreement with Cartessa Aesthetics, which is expected to enhance its product offerings in the cosmetic sector. As of June 30, 2025, the company had cash and cash equivalents of $1,555,251, a significant increase from $547,890 at the end of 2024, although its working capital decreased to $3,926,572 from $7,395,815.

The filing also highlighted the company's ongoing challenges, including a substantial accumulated deficit of $163,674,777 as of June 30, 2025. The company anticipates continued net losses and negative cash flows as it executes its development plans. BioRestorative Therapies has raised approximately $2 million through an at-the-market offering and plans to continue funding its operations through existing cash, marketable securities, and potential future financing. However, the company expressed concerns about its ability to sustain operations without additional capital, raising doubts about its ability to continue as a going concern for at least the next twelve months.

Looking ahead, BioRestorative Therapies aims to enhance its product development and commercialization efforts while navigating the complexities of the therapeutic regulatory environment. The company is committed to addressing its financial challenges and improving its operational efficiency, with management actively working on remediating identified weaknesses in internal controls over financial reporting.